Ivonescimab

DB18931InvestigationalProtein Based Therapies

Ivonescimab is under investigation in clinical trial NCT05184712 (Phase 3 Clinical Study of AK112 for NSCLC Patients).

Mechanism: Pharmacologically active on Programmed cell death protein 1 and Vascular endothelial growth factor A, long form
Curator reviewed
Also known as: IMMUNOGLOBULIN G1 (240-ALANINE,241-ALANINE), ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A) (HUMAN-MUS MUSCULUS MONOCLONAL AK112 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN PROGRAMMED CELL
Code names: AK-112 · SMT-112

Resolves to

Compound

Targets

What you can answer from here — as of October 25, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

161Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ivonescimab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.